Literature DB >> 24238053

Effect of reoperation on outcomes in papillary thyroid cancer.

Stephanie Young1, Avital Harari, Stephanie Smooke-Praw, Philip H G Ituarte, Michael W Yeh.   

Abstract

BACKGROUND: The influence of lymph node recurrences of papillary thyroid carcinoma (PTC) on overall prognosis is uncertain. We performed a population-based, longitudinal analysis to evaluate the impact of reoperation on mortality.
METHODS: Patients who underwent initial operation for PTC >1 cm were abstracted from the California Cancer Registry database (1999-2008). Reoperation was defined as any lymph node dissection after total or near-total thyroidectomy.
RESULTS: Of the 11,986 patients included in the study, 222 (1.9%) underwent one or more reoperations. The median time to reoperation was 8.7 months, with 58.6% and 83.8% of reoperations being performed within 1 and 2 years of initial thyroidectomy, respectively. The mortality rate from PTC was 2.3% (271 patients). After we adjusted for age, sex, tumor size, stage, and radioactive iodine treatment, we found that reoperation was associated with an increased risk of all-cause mortality in patients ≥45 years of age (hazard ratio [HR] 1.51, P < .05). Reoperation was associated with an increased risk of disease-specific mortality in both patients <45 (HR 6.22, P < .01) and ≥45 (HR 2.49, P < .001).
CONCLUSION: Reoperation is independently associated with mortality in PTC. Most reoperations are performed soon after initial thyroidectomy and likely reflect persistent rather than recurrent disease.
Copyright © 2013 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24238053     DOI: 10.1016/j.surg.2013.06.043

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  21 in total

1.  An International Multi-Institutional Validation of Age 55 Years as a Cutoff for Risk Stratification in the AJCC/UICC Staging System for Well-Differentiated Thyroid Cancer.

Authors:  Iain J Nixon; Laura Y Wang; Jocelyn C Migliacci; Antoine Eskander; Michael J Campbell; Ahmad Aniss; Lilah Morris; Fernanda Vaisman; Rossana Corbo; Denise Momesso; Mario Vaisman; Andre Carvalho; Diana Learoyd; William D Leslie; Richard W Nason; Deborah Kuk; Volkert Wreesmann; Luc Morris; Frank L Palmer; Ian Ganly; Snehal G Patel; Bhuvanesh Singh; R Michael Tuttle; Ashok R Shaha; Mithat Gönen; K Alok Pathak; Wen T Shen; Mark Sywak; Luis Kowalski; Jeremy Freeman; Nancy Perrier; Jatin P Shah
Journal:  Thyroid       Date:  2016-02-25       Impact factor: 6.568

2.  Role of RAI in the management of incidental N1a disease in papillary thyroid cancer.

Authors:  Laura Y Wang; Frank L Palmer; Jocelyn C Migliacci; Iain J Nixon; Ashok R Shaha; Jatin P Shah; Robert Michael Tuttle; Snehal G Patel; Ian Ganly
Journal:  Clin Endocrinol (Oxf)       Date:  2015-07-03       Impact factor: 3.478

3.  Outcomes for patients with papillary thyroid cancer who do not undergo prophylactic central neck dissection.

Authors:  I J Nixon; L Y Wang; I Ganly; S G Patel; L G Morris; J C Migliacci; R M Tuttle; J P Shah; A R Shaha
Journal:  Br J Surg       Date:  2015-10-29       Impact factor: 6.939

Review 4.  [Importance of PET for surgery of recurrent thyroid cancer].

Authors:  C Haane; M Colombo-Benkmann
Journal:  Chirurg       Date:  2014-06       Impact factor: 0.955

5.  Previous External Beam Radiation Treatment Exposure Does Not Confer Worse Outcome for Patients with Differentiated Thyroid Cancer.

Authors:  Manish A Shaha; Laura Y Wang; Jocelyn C Migliacci; Frank L Palmer; Iain J Nixon; R Michael Tuttle; Ashok R Shaha; Jatin P Shah; Snehal G Patel; Ian Ganly
Journal:  Thyroid       Date:  2017-02-16       Impact factor: 6.568

6.  Predictors of Neck Reoperation and Mortality After Initial Total Thyroidectomy for Differentiated Thyroid Cancer.

Authors:  Thomas J Semrad; Theresa H M Keegan; Alison Semrad; Ann Brunson; D Gregory Farwell
Journal:  Thyroid       Date:  2018-07-26       Impact factor: 6.568

7.  Management and outcome of clinically evident neck recurrence in patients with papillary thyroid cancer.

Authors:  Laura Y Wang; Jocelyn C Migliacci; R Michael Tuttle; Ashok R Shaha; Jatin P Shah; Snehal G Patel; Ian Ganly
Journal:  Clin Endocrinol (Oxf)       Date:  2017-06-14       Impact factor: 3.478

8.  Association of Radioactive Iodine Administration After Reoperation With Outcomes Among Patients With Recurrent or Persistent Papillary Thyroid Cancer.

Authors:  Matthew L Hung; James X Wu; Ning Li; Masha J Livhits; Michael W Yeh
Journal:  JAMA Surg       Date:  2018-12-01       Impact factor: 14.766

9.  Cost-effectiveness analysis of papillary thyroid cancer surveillance.

Authors:  Laura Y Wang; Benjamin R Roman; Jocelyn C Migliacci; Frank L Palmer; R Michael Tuttle; Ashok R Shaha; Jatin P Shah; Snehal G Patel; Ian Ganly
Journal:  Cancer       Date:  2015-08-17       Impact factor: 6.860

10.  Prognostic impact of incomplete surgical clearance of radioiodine sensitive local lymph node metastases diagnosed by post-operative (124)I-NaI-PET/CT in patients with papillary thyroid cancer.

Authors:  Amir Sabet; Ina Binse; Hong Grafe; Samer Ezziddin; Rainer Görges; Thorsten D Poeppel; Andreas Bockisch; Sandra J Rosenbaum-Krumme
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-04-27       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.